Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC : Episode 4
Opinion
Video
The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC
Author(s):
Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.
Related Videos
Related Content
